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Abstract:
Objective: Intrapleural fibrinolytic enzymes have been used for over 60 years in the treatment
of complicated pleural effusions to lyse loculations and promote resolution. Despite this
extensive history of use, however, little is known about complications that may arise with the
use of this therapy. Here we discuss a patient with chronic renal failure on hemodialysis who
developed an intrapleural hemorrhage after the administration of intrapleural tPA to treat a
complicated parapneumonic effusion. A review of the literature examines the efficacy and
safety of this therapy, focusing on bleeding complications. Specific attention is paid to patients
who have underlying coagulopathies or who are receiving anticoagulation.
Data sources: A review of the literature, as indexed in PubMed, was undertaken using the
following search terms in combination: tPA, pleural effusion, complications of thrombolytics,
and intrapleural hemorrhage. The search was inclusive of patients under the age of 18, but was
limited by English language and human subjects.
Study selection/data extraction: All relevant articles identified during the search were
reviewed. Those studies that reported on bleeding complications, or lack thereof, were
included in this review. Limitations of each article are noted in the text.
Conclusions: Multiple studies, including a 2000 ACP consensus statement and a 2008
Cochrane review, indicate the need for further investigations to evaluate the safety and efficacy
of intrapleural thrombolytics for the treatment of complicated pleural effusions and empye-
mas. Limited studies specifically address bleeding complications, especially in subpopulations
of patients receiving concurrent anticoagulant therapy.
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Introduction
Fibrinolytic enzymes have been used for over 60
years in the treatment of complicated pleural effu-
sions. Injected intrapleurally, they promote resolu-
tion by lysing loculations. Despite an extensive
history of use, however, little is known about
adverse events that may arise with the use of this
therapy. Potential bleeding complications have
been well documented with systemic fibrinolytics
in the treatment of massive pulmonary embolism,
but the literature is sparse regarding complications
associated with intrapleural administration.
Case report
A 40-year-old male with a history of HIV on anti-
retroviral therapy (CD4 354) and end-stage renal
disease from insulin-dependent diabetes mellitus
presented to the emergency department with com-
plaints of fevers, chills and generalized malaise.
Ensuing workup revealed a left lower lobe infiltrate
with a small associated effusion. Blood cultures
ultimately grew Enterococcus. During his hospitali-
zation, the patient underwent two thoracenteses,
which yielded 400 ml and 100 ml of exudative
fluid. Pleural fluid characteristics are noted in
Box 1. Despite treatment with antibiotics, thora-
centeses and continued hemodialysis, the left-sided
pleural effusion continued to enlarge and became
loculated. Computed tomography revealed the
effusion to be complex. Pulmonary consult recom-
mended placement of a pigtail catheter by vascular
interventional radiology. Pigtail catheter insertion
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was attempted but scant fluid was obtained.
Cardiothoracic surgery then placed a chest tube
but due to loculations within the fluid, poor chest
tube output was noted. The patient received alte-
plase (25 mg/100 ml NS) infused through the chest
tube intending to lyse the loculations in the com-
plicated effusion. He developed chest pain and
about 1 liter of serosanguinous fluid drained
through the chest tube. Despite transfusion of
two units of packed red blood cells, his hemoglobin
dropped by 1 g. He was stabilized in the MICU
overnight.
Five days later, due to persistent pleural effusion
and low chest tube output, he again received alte-
plase in the pleural space. Upon unclamping the
tube after 4 h, he was noted to have greater than
600 ml of blood from the chest tube. The patient
was then noted to have signs and symptoms of
hypovolemic shock, with hypotension and tachy-
cardia. Agonal breathing ensued and the patient
went into cardiac arrest with pulseless electrical
activity. He was successfully resuscitated; how-
ever, his hemoglobin dropped from 9.6 g/dl to
3.7 g/dl. The patient underwent emergent thora-
cotomy. Upon entrance into the thoracic space,
significant amount of clot was identified. After
evacuation of his hemothorax, no single source
of bleeding was identified, yet the patient contin-
ued to have diffuse bleeding. The patient’s coag-
ulation parameters that were initially normal were
elevated. The international normalized ration
(INR) increased from 1.5 s to 2.0 s; the activated
partial thromboplastin (aPTT) increased from
38.6 s to 84.7 s. The D-dimer was 14,762 ng/ml
(normal 0229 ng/ml); fibrinogen was elevated
to 481 mg/dl (normal 208409 mg/dl). Platelets,
fresh frozen plasma, cryoprecipitate, and activated
factor VII were given with resolution of the bleed-
ing. The patient’s thoracotomy incision was
closed and the patient did not have any further
blood loss.
Review of the literature
Intrapleural fibrinolytic enzymes have been used
since the late 1940s to lyse fibrinous loculations
within pleural fluid, decrease viscosity, and pro-
mote resolution of complicated pleural effusions
[Tillett and Sherry 1949]. Varying success
rates have been reported in the literature. First-
generation thrombolytics, such as streptokinase
and urokinase, have no fibrin binding capabilities
and exert their effects via increasing local gener-
ation of plasmin [Longstaff et al. 2008]. Initial
studies evaluated streptokinase, which ultimately
lost favor due to concerns over systemic side
effects, such as delayed hypersensitivity reactions.
Urokinase was introduced and thought to
have a lower incidence of adverse events, but
marketing was ceased under a Food and Drug
Administration mandate over concerns of possi-
ble transmission of viral diseases. As a second-
generation fibrinolytic with high specificity for
fibrin and a short half-life, recombinant human
tissue plasminogen activator (tPA) has become
the agent of choice since 1998, despite its
increased cost.
Potential bleeding complications have been well
demonstrated in studies examining the use of sys-
temic tPA for massive pulmonary embolism.
Meyer et al. [1998] established that major bleed-
ing occurred in 25% of 132 adult patients receiv-
ing tPA for pulmonary embolism, including
hematoma at the puncture site for pulmonary
angiography, ecchymosis, and hemoptysis. The
authors also note that the bleeding rates in
other studies may vary depending on the criteria
used to define bleeding.
In 2000, the American College of Chest
Physicians (ACCP) published a consensus state-
ment of evidence-based guidelines for the man-
agement of parapneumonic effusions [Colice
et al. 2000]. An important notation was that
only three randomized, controlled clinical trials
had been performed, involving less than 100
patients, and significant methodological inconsis-
tencies limited the generalizability of the data.
The panel acknowledged that conclusions were
unable to be drawn about the defining patient
characteristics that would increase the likelihood
of success with fibrinolytics. Limited data were
available about adverse reactions.
A more recent meta-analysis [Tokuda et al. 2006],
published after the ACCP consensus statement,
indicated that intrapleural fibrinolytics did not
Box 1. Pleural fluid characteristics.
Gram stain: 1 + polymorphonuclear cells, no
organisms seen
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reduce mortality or the need for surgery in adult
patients with empyema or complicated parapneu-
monic effusion. Significant heterogeneity was
noted amongst the trials used for the meta-analy-
sis, however. Two studies [Bouros et al. 1999;
Davies et al. 1999] which had been referenced in
the 2000 ACCP consensus statement and three
additional studies [Maskell et al. 2005; Diacon
et al. 2004; Tuncozgur et al. 2001] were included
in the meta-analysis. The authors note that while
the smaller sample-size studies reported a positive
effect with fibrinolytics, the larger trial MISTI
[Maskell et al. 2005] (208 patients) reported no
improvement in death rates, length of hospitaliza-
tion, radiographic changes or progression to sur-
gery. Tokuda et al. [2006] explain that since there
was significant heterogeneity among the patient
populations and treatment effects, it is possible
that intrapleural fibrinolytics may have a role in
select patient populations. Despite the limitations
of the available data, the use of fibrinolytics
remains a common means of increasing drainage
from a loculated pleural effusion from a variety of
patients [Levinson and Pennington 2007; Hsu
et al. 2006; Ekingen et al. 2004; Feola et al. 2003].
Few of the early studies have reported hemor-
rhagic complications associated with intrapleural
fibrinolytics. Jerjes-Sanchez et al. [1996] claimed
an efficacy rate of 92% and reported no hemor-
rhagic complications in 48 patients with loculated
pleural effusions that were treated using strepto-
kinase. Davies et al. [1997] examined the sys-
temic fibrinolytic activity of streptokinase and
noted no significant systemic effects stemming
from intrapleural administration. Moulton et al.
[1995] treated 98 patients with complicated
pleural effusions with intrapleural administration
of urokinase and noted no systemic bleeding
complications during therapy. They did report
‘occasionally an effusion that was initially nonhe-
morrhagic would become bloody during the final
UK aspirations, but this was always a small
amount of dark lysed blood and was never
active bleeding’. Coagulation parameters were
not measured. Further details regarding this
bleeding were not available. Sahn [1997]
reported on 24 patients with infected parapneu-
monic effusions who received intrapleural strep-
tokinase and had a significant improvement
in the drainage of pleural fluid; no bleeding or
systemic fibrinolysis complications were noted.
Bouros et al. [1997] compared streptokinase
with urokinase and found similar efficacies and
no increase in adverse reactions other than fevers
in 8% of the streptokinase arm. Cochran [2003]
reported retrospectively on 19 pediatric patients
with complicated pleural effusions persisting
despite tube thoracostomy and noted that intra-
pleural administration of either urokinase
(13 patients) or streptokinase (six patients)
increased the volume of pleural fluid drainage
and allowed for 14 of the patients to be success-
fully managed without surgical intervention.
There were no significant adverse events or side
effects in this cohort.
After 1998 when urokinase was withdrawn from
the market, studies involving alteplase (recombi-
nant human tPA) were initiated. Bishop et al.
[2003] reported resolution of a complicated para-
pneumonic effusion in a 16-month-old girl after
the administration of five doses of intrapleural
tPA at a dose of 2 mg, the recommended dose
for clearance of thrombi from central venous
catheters. Skeete et al. [2004] completed a
4-year retrospective analysis of 41 patients, all
of whom showed radiographic improvement
after administration of tPA for pleural effusions.
The etiologies of the effusions were varied and
included 14% traumatic, 52% loculated pleural
effusions, 29% empyemas and 5% line-associated
hemothoraces. Six patients required blood trans-
fusion within 48 hours of tPA administration, for
reasons ranging from Coombs-positive hemolytic
anemia, to hypotension after chest tube clamp-
ing, to hematuria while undergoing hemodialysis.
No patient developed intrathoracic bleeding.
Thommi et al. [2007] reported on 120 patients
who were treated with recombinant tissue plas-
minogen activator (tPA) for persistent compli-
cated pleural effusion or empyema after simple
chest tube placement. Bolus doses of intrapleural
alteplase ranged from 10 to 100 mg, using lower
doses (1025 mg) for complicated malignant
pleural effusions and higher doses (50100 mg)
for empyema. Up to eight doses were adminis-
tered until there was significant reduction in the
size of the pleural effusion and improved clinical
signs of sepsis or if the return pleural fluid
became increasingly bloody. Reported complica-
tions included chest pain in seven patients (6%)
and bleeding at the site of the chest tube in two
patients (2%). One patient who received the
50 mg dose required blood transfusion, although
it is not reported if that patient developed
hemothorax or another site of bleeding. It is
also unclear whether any of these patients were
receiving concomitant anticoagulants. Weinstein
et al. [2004] compared outcomes of complicated
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parapneumonic effusions in 12 children who
received early tPA (within 24 h of diagnosis),
18 children with late tPA (> 24 h after diagnosis),
and 23 children managed with tube thoracost-
omy only. Rate of fluid removal was highest for
the early tPA group (7 ml/h versus 3 ml/h in the
tube-only group), whereas total fluid drainage
was highest for the late tPA group (691 ml
versus 360 ml in the tube-only group). No local
or systemic bleeding events were reported.
Froudarakis et al. [2008] administered 25 units
of intrapleural tPA into 20 consecutive patients
with empyema or complicated pleural effusions
who failed simple chest tube drainage. Clinical
resolution was noted in all but one patient; how-
ever, there were three cases (15%) of mild local
hemorrhage, which did not result in discontinua-
tion of tPA. Coagulation profiles of all patients
showed no significant changes.
Most recently, a 2008 Cochrane literature review
by Cameron and Davies was conducted to eval-
uate the benefits and safety of intrapleural fibri-
nolytics. Searches were conducted through
November 2006, updating a previous review in
2004. Endpoints of interest were reduction in
mortality and avoidance of intrathoracic surgery.
Conclusions were that intrapleural fibrinolytic
agents were useful in decreasing the need for sur-
gical intervention in patients with empyema or
complicated parapneumonic effusion. Similar to
what was noted in the meta-analysis by Tokuda
[2006], the MISTI [Maskell et al. 2005] trial
carried the greatest weight and was the only
included study to report adverse event data.
The authors note that statistically, intrapleural
fibrinolytics have not been shown to increase
adverse events, but a wide confidence interval
makes it difficult to completely exclude this
possibility.
Since the publication of the Cochrane review,
another study has added to the knowledge
regarding adverse events with intrapleural tPA
administration. A recent retrospective review
[Gervais et al. 2008] examined the risk for hem-
orrhage with tPA administered twice a day via
chest tube in a dose of 46 mg diluted in 50 ml
normal saline, left to dwell for 30 min. Over
6 years, 2241 catheters were placed under ima-
ging guidance in 2089 patients. Out of 66
patients who had tPA instilled through the
chest tube, 12 were receiving systemic anticoagu-
lation for other reasons. Out of these, five intra-
pleural hemorrhages occurred in four patients.
This included one patient receiving warfarin,
one patient receiving low-molecular-weight
heparin, and two receiving unfractionated
heparin. Out of the remaining 54 patients who
were not receiving full systemic anticoagulation,
38 were the recipients of prophylactic subcutane-
ous heparin. None of these patients bled. Two of
the 66 patients were receiving clopidogrel, and
neither bled, even though one was also receiving
intravenous heparin. Twelve of the 66 patients
were receiving aspirin; seven of the 12 were
receiving both systemic anticoagulation and
aspirin, and two of these seven bled. The authors
concluded that the hemorrhages occurred only in
patients who were receiving therapeutic anticoa-
gulation and in no patients who were receiving
prophylactic anticoagulation (p<0.01). They
provided no data on PT/PTT measurements or
platelet counts, nor any mention of patients who
were uremic or on hemodialysis. The authors
quote an effectiveness rate of 86% and note intra-
pleural tPA to be safe in patients receiving simul-
taneous prophylactic anticoagulation; however,
patients receiving therapeutic anticoagulation
and intrapleural tPA had a significantly higher
risk of pleural hemorrhage.
One question that remains unanswered is the
issue regarding fibrin-specific fibrinolytics. In
the ASSENT-2 trial [1999], which compared
tPA to tenecteplase (TNK-tPA), a variant of
tPA with higher fibrin specificity, in the treatment
of myocardial infarction, significantly fewer
patients who received TNK-tPA experienced
adverse bleeding complications. The rates of
cerebral bleeding were not significant different,
however. Van de Werf et al. [2001] noted that
the difference in bleeding complications was
most profound in female patients greater than
75 years of age and with low body weights
(< 67 kg). The authors speculated that lower
doses of concomitant heparin contribute to
lower rates of bleeding complications. A longer
half-life of tenecteplase (22 minutes, as compared
with 48 minutes for alteplase) may allow for
decreased frequency of administration. Szabo
et al. [2002] also elegantly showed paradoxical
thrombin activation in patients with acute myo-
cardial infarction who received tPA, but lower
levels of thrombin-antithrombin III complexes
and a lower extent of activation of the kallik-
rein-factor XII system in those patients who
received TNK-tPA. They concluded that tenec-
teplase has higher fibrin specificity than alteplase.
To our knowledge, similar trials have not been
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conducted comparing the use of tenecteplase
versus alteplase for intrapleural fibrinolysis.
The use of tPA for drainage of complex fluid
collections is not limited to the pleural space.
Beland et al. [2008] injected 46 mg twice a
day via percutaneous abdominal drains for
complex abdominal and pelvic abscesses, and
reported no tPA-associated bleeding complica-
tions despite four patients receiving full systemic
anticoagulation and 24 patients receiving prophy-
lactic anticoagulation.
Our patient was not receiving systemic anticoa-
gulation. However, multiple factors affected his
clotting during this hospitalization. First, as a
dialysis-dependent patient, he was treated with
heparin three times weekly during his dialysis ses-
sions. He also had a history of coronary artery
disease, which resulted in him taking a daily
aspirin. Additionally, earlier in his hospital
course, he did suffer from vitamin K deficiency
due to nutritional deprivation. He was repleted
with vitamin K but on the day of the first
hemothorax, his PTand PTT were still prolonged
at 15.4 and 39.5 s, respectively. We also speculate
that uremic platelet dysfunction may have con-
tributed to his hemothorax, since the tPA was
administered and the hemothoraces occurred on
nondialysis days. Despite the fact that he was
receiving hemodialysis, dialysis has not been
shown to have a consistent effect on improving
platelet function [Hedges et al. 2007]. Therefore,
the instillation of tPA may have disrupted his ten-
uous balance of coagulant factors and resulted in
a life-threatening hemothorax. We suggest that in
patients with chronic renal failure, physicians
should refrain from the use of currently available
intrapleural fibrinolytics for complicated effusion
until further studies define the safety and efficacy
in this patient population.
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